BNET Industries

Sepracor Inc.

(SEPR) is in the Pharma Industry

Last Fiscal Year Sales:$1.2B
  • Public
  • US
Dow Jones Description

Founded in 1984, Sepracor was originally comprised of several diverse business units. In 1989, we embarked on a strategy of developing single isomers and active metabolites of many of the world's largest selling drugs, with the objective of developing our own proprietary pipeline of pharmaceutical products. Sepracor became a publicly traded corporation in 1991, and we subsequently divested our non-pharmaceutical business units into four different companies, retaining our core pharmaceutical business. Sepracor was built on the premise that chiral drugs could, in essence, be divided into two or more "parts" and that certain of these parts could be brought to the market as new medicines with the possibility for reduced side effects, greater potency or new indications. Sepracor was a pioneer in this area of drug development, identifying new, viable compounds. This strategy enabled Sepracor to establish itself initially by out-licensing the rights to a number of compounds to large, established pharmaceutical companies who developed and ultimately commercialized them. Some of these compounds have grown to become well-known brands in the pharmaceutical industry: ALLEGRA brand fexofenadine HCl, CLARINEX brand desloratadine and XYZAL /XUSALTM brand levocetirizine. ...

Number of Employees 2,400
Contact Information

84 Waterford Dr

Marlborough, Massachusetts 01752

sepracor.com

(508) 481-6700

NAICS Code Pharmaceutical and Medicine Manufacturing: 3254

Recent Events

  • Sepracor's Lunesta patent extended

    12/18/09 - Bond / Stock Rating - View Story

  • Sepracor CEO in line for $11M golden handshake

    10/22/09 - Merger / Acquisition - View Story

  • Data Missing On US Drug Labels

    10/23/09 - Financial Announcement - View Story

  • Sepracor deal closes, CEO in line for $11M

    10/21/09 - Merger / Acquisition - View Story

  • Standard & Poor's Announces Changes To U.S. Indices - Update

    10/07/09 - Merger / Acquisition - View Story

  • Dainippon Sumitomo To Acquire Sepracor For $2.6 Bln - Update

    9/03/09 - Merger / Acquisition - View Story

  • Dainippon to buy U.S. drug firm Sepracor for $2.6 billion

    9/03/09 - Financial Announcement - View Story

  • Japan firm acquires US drug maker Sepracor

    9/04/09 - Merger / Acquisition - View Story

  • Zacks Industry Rank Analysis Highlights: CVS Caremark, Life Technology, NuVasive, Inc., Sepracor and Gilead Sciences

    8/10/09 - Financial Announcement - View Story

  • Zacks Industry Rank Analysis Highlights: CVS Caremark, Life Technology, NuVasive, Inc.,...

    8/06/09 - Financial Announcement - View Story

  • Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of XyzalR Solution and...

    6/24/09 - Lawsuit Filed - View Story

News & Analysis

revenue and sepracor inc. - All News and Analysis

Presented by American Express